Stock AQST AQUESTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Aquestive Therapeutics, Inc. Share Price

Equities

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 01:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
3.735 USD -8.23% Intraday chart for Aquestive Therapeutics, Inc. -14.73% +84.90%
29/04 Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children MT
29/04 Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film CI

Financials

Sales 2024 * 50.21M 4.19B Sales 2025 * 57.98M 4.84B Capitalization 340M 28.36B
Net income 2024 * -27M -2.25B Net income 2025 * -27M -2.25B EV / Sales 2024 * 6.37 x
Net cash position 2024 * 20.23M 1.69B Net Debt 2025 * 15.47M 1.29B EV / Sales 2025 * 6.13 x
P/E ratio 2024 *
-10.4 x
P/E ratio 2025 *
-12.7 x
Employees 135
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95%
More Fundamentals * Assessed data

Chart Aquestive Therapeutics, Inc.

Dynamic Chart

Latest news about Aquestive Therapeutics, Inc.

Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children MT
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film CI
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology CI
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target MT
Aquestive Therapeutics Files $250 Million Mixed Shelf MT
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024 CI
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Steady Premarket Wednesday MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply MT
Top Premarket Decliners MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating MT
More news

Latest transcript on Aquestive Therapeutics, Inc.

Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. - Special Call
More transcripts

Analyst Recommendations on Aquestive Therapeutics, Inc.

Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target MT
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating MT
More recommendations

Press releases Aquestive Therapeutics, Inc.

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film GL
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET GL
Aquestive Therapeutics to Present Crossover Study Data for Libervant Buccal Film at 76th Annual Meeting of the American Academy of Neurology AQ
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology GL
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive GL
More press releases

News in other languages on Aquestive Therapeutics, Inc.

Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
More news

Quotes and Performance

1 day-8.23%
1 week-14.73%
Current month-12.32%
1 month-12.32%
3 months+51.83%
6 months+163.03%
Current year+84.90%
More quotes

Highs and lows

1 week
3.24
Extreme 3.24
4.28
1 month
3.24
Extreme 3.24
4.54
Current year
1.95
Extreme 1.95
6.23
1 year
1.25
Extreme 1.2514
6.23
3 years
0.62
Extreme 0.618
6.40
5 years
0.62
Extreme 0.618
10.00
10 years
0.62
Extreme 0.618
20.70
More quotes

Managers and Directors - Aquestive Therapeutics, Inc.

Managers TitleAgeSince
Daniel Barber CEO
 Chief Executive Officer 48 01/07/01
A. Toth DFI
 Director of Finance/CFO 65 31/20/31
Stephen Wargacki CTO
 Chief Tech/Sci/R&D Officer 46 01/15/01
Members of the board TitleAgeSince
Timothy Morris BRD
 Director/Board Member 61 10/22/10
Santo Costa CHM
 Chairman 78 01/15/01
Gregory Brown BRD
 Director/Board Member 70 01/07/01
More insiders

Quotes

Date Price Change Volume
29/24/29 3.735 -8.23% 7,632,648
26/24/26 4.07 +3.56% 2,986,647
25/24/25 3.93 +0.77% 1,935,903
24/24/24 3.9 -8.88% 2,147,676
23/24/23 4.28 -2.28% 1,699,537

Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST

More quotes

Company Profile

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.
Sector
Pharmaceuticals
Calendar
07/05/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Aquestive Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.735 USD
Average target price
9.125 USD
Spread / Average Target
+144.31%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AQUESTIVE THERAPEUTICS, INC. Stock Aquestive Therapeutics, Inc.
+84.90% 371M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AQST Stock